Cargando…

Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	McGoran, John, Wilson, Alan, McErlain, Shannan, Kennedy, Noreen, Masterson, Caroline, Collins, Caroline, Morrison, Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666859/ https://www.ncbi.nlm.nih.gov/pubmed/34966537 http://dx.doi.org/10.1136/flgastro-2020-101760

Ejemplares similares

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries
por: Jha, Ashok, et al.
Publicado: (2015)

Physicochemical characterization of Remsima®
por: Jung, Soon Kwan, et al.
Publicado: (2014)

Performance of Remsima® Monitor Drug Level versus RIDASCREEN IFX Monitoring in therapeutic drug monitoring of infliximab in patients with inflammatory bowel disease: A study of diagnostic accuracy
por: Song, Joo Hye, et al.
Publicado: (2022)

Post Flywheel Squat Potentiation of Vertical and Horizontal Ground Reaction Force Parameters during Jumps and Changes of Direction
por: McErlain-Naylor, Stuart A., et al.
Publicado: (2021)

Palladium-Catalyzed C–P Bond-Forming Reactions of Aryl Nonaflates Accelerated by Iodide
por: McErlain, Holly, et al.
Publicado: (2021)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

An in vivo investigation of the initiation and progression of subchondral cysts in a rodent model of secondary osteoarthritis
por: McErlain, David D, et al.
Publicado: (2012)

The Effect of Flywheel Inertia on Peak Power and Its Inter-session Reliability During Two Unilateral Hamstring Exercises: Leg Curl and Hip Extension
por: de Keijzer, Kevin L., et al.
Publicado: (2022)

On-field rehabilitation in football: Current knowledge, applications and future directions
por: Armitage, Mark, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(®) to Remsima(®)? An Observational Study
por: Xue, Laixi, et al.
Publicado: (2020)

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
por: Baik, Deborah, et al.
Publicado: (2022)

Perception and application of flywheel training by professional soccer practitioners
por: de Keijzer, Kevin L., et al.
Publicado: (2021)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Organocatalytic Asymmetric Synthesis of SynVesT-1, a Synaptic Density Positron Emission Tomography Imaging Agent
por: McErlain, Holly, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
por: Little, Robert D., et al.
Publicado: (2022)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Evaluation of the physicochemical and functional stability of diluted REMSIMA(®) upon extended storage—A study compliant with NHS (UK) guidance
por: Young, Benjamin L., et al.
Publicado: (2015)

Remsima (a Tumor Necrosis Factor (TNF) -α Inhibitor) induced hemolysis in a patient with Crohn's disease - Case report
por: AL-Ansari, Rehab Y., et al.
Publicado: (2021)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Update on the management of the gastrointestinal effects of radiation
por: McCaughan, Hannah, et al.
Publicado: (2021)

Post-activation potentiation effect of eccentric overload and traditional weightlifting exercise on jumping and sprinting performance in male athletes
por: Beato, Marco, et al.
Publicado: (2019)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
por: Cerna, Karin, et al.
Publicado: (2023)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Correction: Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis
por: Appleton, C Thomas G, et al.
Publicado: (2008)

Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis
por: Appleton, C Thomas G, et al.
Publicado: (2007)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
por: Smith, Philip J, et al.
Publicado: (2022)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
por: Yoo, Hyun Kyeong, et al.
Publicado: (2022)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ar3q2sqqpcbimougg4qtbfeg8